A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Summary

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

Timeline

Start

2026-06-01

Primary completion

2028-10-25

Completion

2031-10-16

Drugs

Indications